Carbamazepine Overdose after Psychiatric Conditions: A Case Study for Postmortem Analysis in Human Bone.

Carbamazepine is the main option used as a preventive medication to treat bipolar disorder when there is no response to lithium. Carbamazepine toxicity is defined as serum levels greater than 12 µg/mL, with severe toxicity occurring over 40 µg/mL, reduced to 30 µg/mL when combined with pharmacological treatment, i.e., benzodiazepines or antidepressants. For these reasons, it is necessary to find a validated tool to determine carbamazepine levels in an autopsy to rule out suicide or to know if the death was a consequence of an adverse drug reaction (ADR), especially when only bones can be accessed. We have validated a tool to detect and quantify drug concentration in bone. Our results showed a peak for carbamazepine at minute 12 and a mass fragment of 193 m/z. This case study is the first time in the literature that carbamazepine has been detected and quantified in bone. These results demonstrate that carbamazepine can be detected in bone tissue from forensic cases, but almost more importantly, that the method proposed is valid, reliable, and trustworthy.

Toxic Elements in Traditional Kohl-Based Eye Cosmetics in Spanish and German Markets.

Kohl is a traditional cosmetic widely used in Asia and Africa. In recent years, demand for kohl-based eyelids and lipsticks has increased in Europe, linked to migratory phenomena of populations from these continents. Although the European legislation prohibits the use of heavy metals in cosmetics due to the harmful effects to human health, particularly to pregnant women and children, these elements are still present in certain products. The European Union recommended levels are Pb < 20 ppm, As < 5 ppm, Cd < 5 ppm, Sb < 100 ppm, and Ni < 200 ppm. In Germany, levels are more restrictive: Pb < 2 ppm, As < 0.5 ppm, Cd < 0.1 ppm, Sb < 0.5 ppm, and Ni < 10 ppm. Here, we analyzed 12 kohl-based cosmetics in different presentations (powder, paste, and pencil) that were purchased in Spanish and German local shops. An inductively coupled plasma optical emission spectrophotometer was used to identify toxic elements and heavy metals. Levels of Pb ranged between 1.7 and 410,000 ppm in six of the study samples, four of which had levels above the recommended limit of at least two heavy metals. Arsenic (a carcinogenic element) values were within the range allowed by the EU in only 58% of the studied samples. Moreover, two products doubled this limit, reaching levels of 9.2 and 12.6 ppm. In one of the products, cadmium, related to toxic keratitis, was four times higher (20.7 ppm) than that allowed, while in two other products, these limits were doubled (11.8 and 12.7 ppm). Our results indicate the need to supervise the manufacture of kohl-based traditional products and the analysis of their composition prior distribution in European countries.

Postmortem analysis of quetiapine and pregabalin in human bone.

In this study quetiapine and pregabalin were analyzed in human bones. A method previously developed for the determination of antidepressants in human bone was tested for the analysis of these two substances. Bones were pulverized and subjected to the extraction protocol, and after undergoing solid-phase extraction, samples were analyzed using gas chromatography-mass spectrometry. The assay was validated in the range 0.3-500 ng/mg, mean analytical recovery was 76.9% for quetiapine and 90.9% for pregabalin, matrix effect was 83% for quetiapine and 91% for pregabalin and process efficiency was 63.8% for quetiapine and 82.7% for pregabalin. The intra- and inter-day precision was below 3% in all cases and the intra- and inter-assay accuracy values were in almost all cases better than 12%. The validated method was then applied to bone samples from forensic cases. Drugs were detected in bone in 2 of the 3 blood positive cases. The approximate concentrations in bone were 40 ng/mg for pregabalin and 7 ng/mg for quetiapine. To our knowledge, this is the first time these substances were detected in bones. With this study the number of substances with a validated protocol to be used in human bones in case of necessity is expanded.

Development and Validation of a Method for the Analysis of Bisoprolol and Atenolol in Human Bone.

A method based on gas chromatography-mass spectrometry (GC-MS) is described for the determination of bisoprolol and atenolol in human bone. After the addition of lobivolol as internal standard, pulverized samples were incubated in acetonitrile for 1 h under ultrasounds. After adjusting the pH of the samples to 6, they were centrifuged, and the supernatants were subjected to solid phase extraction. Elution was achieved by using 3 mL of 2% ammonium hydroxide in 80:20 dichloromethane:isopropanol solution. Eluted samples were evaporated and derivatized. Chromatography was performed on a fused silica capillary column and analytes were determined in the selected-ion-monitoring (SIM) mode. The assay was validated in the range 0.1-0.3 ng/mg (depending on the drug) to 150 ng/mg, the mean absolute recoveries were 60% for bisoprolol and 106% for atenolol, the matrix effect was 69% for bisoprolol and 70% for atenolol and process efficiency was 41% for bisoprolol and 80% for atenolol. The intra- and inter-assay accuracy values were always better than 12%. The validated method was then applied to bone samples from two real forensic cases in which toxicological analysis in blood were positive for atenolol in the first case (0.65 µg/mL) and bisoprolol in the second case (0.06 µg/mL). Atenolol was found in bone samples from the corresponding case at the approximate concentration of 148 ng/mg and bisoprolol was found at 8 ng/mg.

Development and validation of a method for analysing of duloxetine, venlafaxine and amitriptyline in human bone.

A method based on gas chromatography-mass spectrometry (GC-MS) is described for the determination of venlafaxine, amitriptyline and duloxetine in human bone. Pulverized samples were incubated in methanol for 1 h under ultrasonication, after the addition of sertraline as internal standard. The samples were centrifuged, and the supernatants were evaporated. Samples were then resuspended in 0.1 M phosphate buffer pH 6 and subjected to solid phase extraction. Chromatography was performed on a fused silica capillary column and analytes were determined in the selected-ion-monitoring (SIM) mode. The assay was validated in the range 0.3-1 ng/mg (depending on the drug) to 500 ng/mg. The mean absolute recoveries ranged from 92.6% to 96.2%, the matrix effect from 76.9% to 103.3% and process efficiency from 74% to 95.9% depending on the analyte. The intra- and inter-assay accuracy values were always better than 20%. The validated method was then successfully applied to real bone samples from forensic cases in which toxicological analysis for these drugs in blood had been positive. Drugs were detected in bone in all blood positive results, the approximate concentrations being 36.4 ng/mg for amitriptyline, 19.3-3 ng/mg for duloxetine and 4.6-2 ng/mg for venlafaxine.

Development and validation of a gas chromatography-mass spectrometry method for opiates and cocaine in human bone.

A method based on gas chromatography-mass spectrometry (GC-MS) is described for the determination of opioids (6-monoacetylmorphine, morphine, methadone and tramadol) and cocaine and its major metabolite in human bone. After the addition of nalorphine as internal standard, pulverized samples were incubated in acetonitrile for 1 h under ultrasounds. After adjusting the pH of the samples to 6, they were subjected to solid phase extraction and the analytes were eluted using 2 ml of dichloromethane/isopropanol/ammonia (78:20:2). Chromatography was performed on a fused silica capillary column and analytes were determined in the selected-ion-monitoring (SIM) mode. The assay was validated in the range 0.3-1 ng/mg (depending on the drug) to 150 ng/mg, the mean absolute recoveries ranging from 66% to 110%, the matrix effect from 62% to 121% and process efficiency from 61% to 89% depending on the analyte. The intra- and inter-assay accuracy values were always better than 20%. The validated method was then successfully applied to real bone samples from forensic cases in which toxicological analysis for these drugs in blood was positive. Drugs were detected in bone in 12 of the 15 blood positive results. The approximate concentration range was 3-5 ng/g for 6-monoacetylmorphine, 3-7 ng/g for morphine, 14-28 ng/g for methadone and 6 ng/g and 11 ng/g for tramadol and benzoylecgonine.

Conocimientos sobre el tratamiento y baja adhesión terapéutica de los pacientes anticoagulados / Knowledge about treatments and low adherence to therapy of anticoagulated patients

The main objective of this study is to measure health literacy in patients treated with oral anticoagulants and their knowledge about their treatment, and to analyze the relationships between health literacy, knowledge of their treatment, adherence, the occurrence of adverse drug reactions and several demographic and socioeconomic factors. The studied population consisted of patients going to a pharmacy with a medical prescription for oral anticoagulants. We used the abbreviated questionnaire of the European Project of Health Literacy HLS-EU-Q16 to measure health literacy and structured interviews in order to measure general knowledge about the treatment. From 133 patients in treatment with anticoagulants, 49.6% were male and the mean age was 69.72 ± 12.66 years. The levels of health literacy were in accordance with those reported by recent literature, with 51.1% of the sample having an adequate level of health literacy, 33.8% a problematic level and 15% an insufficient level. One in two patients had limited health literacy. Health literacy levels and patient knowledge were poor, and there was a relationship between them. Both decrease with age and increase with formal educational level and perceived socioeconomic status. We found no relationship between self-reported compliance or self-reported complications and health literacy or knowledge. Strategies should be implemented to promote empowerment, especially in chronic patients and those populations with fewer competencies in health information management

El objetivo principal de este trabajo es medir la alfabetización en salud en pacientes anticoagulados y sus conocimientos sobre el tratamiento que están utilizando, y analizar su relación con la adhesión, la aparición de complicaciones derivadas del medicamento y distintos factores sociodemográficos. La población en estudio consistió en pacientes que acuden a la Oficina de Farmacia con prescripción de anticoagulantes orales. Empleamos el cuestionario abreviado del Proyecto Europeo de Alfabetización en Salud HLS-EU-Q16 y realizamos entrevistas para medir los conocimientos sobre el tratamiento. De los 133 pacientes en tratamiento, 49.6% eran hombres y la media de edad era 69.72 ± 12.66 años. Los niveles de alfabetización en salud están en consonancia con los informados en la literatura reciente, de forma que el 51.1% presentaba un nivel de alfabetización en salud suficiente; el 33.8%, problemática, y el 15%, insuficiente. Uno de cada dos pacientes tenía un nivel limitado de alfabetización en salud. Los niveles de alfabetización en salud y el conocimiento de los pacientes son bajos, están relacionados entre sí y disminuyen con la edad, aumentan con el nivel educativo y socioeconómico. No encontramos elación entre la adhesión terapéutica y la aparición de complicaciones con alfabetización en salud o el conocimiento. Es necesario implementar estrategias para favorecer el empoderamiento, especialmente en los enfermos crónicos y los colectivos que presentan menos competencias a la hora de desenvolverse en el manejo de la información en salud

Treatments that generate higher number of adverse drug reactions and their symptoms / Tratamientos que provocan un alto número de reacciones adversas a la medicación y sus síntomas

Objectives. Adverse drug reactions (ADRs) are an important cause of morbidity and mortality worldwide and generate high health costs. Therefore, the aims of this study were to determine the treatments which produce more ADRs in general population and the main symptoms they generate. Methods. An observational, cross-sectional study consisting in performing a self-rated questionnaire was carried out. 510 patients were asked about the treatments, illnesses and ADRs, they had suffered from. Results. 26.7% of patients had suffered from some ADR. Classifying patients according to the type of prescribed treatment and studying the number of ADR that they had, we obtained significant differences (p ≤ 0.05) for treatments against arthrosis, anemia and nervous disorders (anxiety, depression, insomnia). Moreover, determining absolute frequencies of these ADRs appearance in each treatment, higher frequencies were again for drugs against arthrosis (22.6% of patients treated for arthrosis suffered some ADR), anemia (14.28%), nerve disorders (13.44%) and also asthma (16%). Regarding the symptoms produced by ADRs, the most frequent were gastrointestinal (60% of patients who suffered an ADR, had gastrointestinal symptoms) and nervous alterations (dizziness, headache, sleep disturbances etc) (24.6%). Conclusion. Therapeutic groups which produce more commonly ADRs are those for arthrosis, anemia, nervous disorders and asthma. In addition, symptoms which are generated more frequently are gastrointestinal and nervous problems. This is in accordance with the usual side effects of mentioned treatments. Health professionals should be informed about it, so that they would be more alert about a possible emergence of an ADR in these treatments. They also could provide enough information to empower patients and thus, they probably could detect ADR events. This would facilitate ADR detection and would avoid serious consequences generated to both patients' health and health economics

Introducción. Las Reacciones Adversas a Medicamentos (RAM) constituyen una importante fuente de morbilidad y mortalidad en todo el mundo, generando altos costes económicos. Por ello, el objetivo de este estudio fue determinar aquellos tratamientos que producen una mayor cantidad de RAM en la población general así como conocer los principales síntomas que generan. Material y métodos. Se realizó un estudio transversal observacional mediante la cumplimentación de un cuestionario. Para ello, 510 pacientes fueron encuestados sobre qué patologías tenían diagnosticadas, sus tratamientos farmacológicos y las RAM sufridas. Resultados. Un 26,7% de los pacientes encuestados había sufrido alguna RAM. Obtuvimos resultados estadísticamente significativos (p ≤ 0.05) al clasificar a los pacientes según el tratamiento prescrito y el número de RAM sufridas para los tratamientos farmacológicos de artrosis, anemia y enfermedades del sistema nervioso (ansiedad, depresión, insomnio). Además cuantificamos frecuencias de aparición de RAM mayores en aquellos fármacos prescritos contra la artrosis (22,6% de los casos sufrieron RAM), anemia (14,28%), alteraciones nerviosas (13,44%) y asma (16%). En cuanto a los síntomas producidos, los más frecuentes fueron gastrointestinales (60% de los pacientes) y alteraciones nerviosas (mareos, dolor de cabeza, problemas de conciliación del sueño etc, 24,6%). Discusión. La principal conclusión de nuestro estudio es que aquellos fármacos que producen mayor número de RAM están prescritos para el tratamiento de la artrosis, la anemia, las alteraciones nerviosas y el asma. Además, los síntomas que aparecen principalmente tras una RAM son alteraciones gastrointestinales y nerviosas. Los profesionales sanitarios deberían estar alerta ante la posible aparición de RAM en dichos tratamientos y proporcionar a sus pacientes el empoderamiento necesario para que ellos mismos pudieran detectarse RAM. Esto evitaría consecuencias negativas tanto en su estado de salud como en el gasto sanitario

Tromboembolia pulmonar en un paciente con trombofilia familiar de origen genético debida a homocigosis en mutación 20209C>T / Pulmonary embolism in a patient with familial thrombophilia due to homozygotic genetic mutation in 20209C>T

No disponible